GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Sangui Biotech International Inc (OTCPK:SGBI) » Definitions » Forward PE Ratio

Sangui Biotech International (Sangui Biotech International) Forward PE Ratio : 0.00 (As of Apr. 28, 2024)


View and export this data going back to . Start your Free Trial

What is Sangui Biotech International Forward PE Ratio?

Sangui Biotech International's Forward PE Ratio for today is 0.00.

Sangui Biotech International's PE Ratio without NRI for today is 0.00.

Sangui Biotech International's PE Ratio for today is 0.00.


Sangui Biotech International Forward PE Ratio Historical Data

The historical data trend for Sangui Biotech International's Forward PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sangui Biotech International Forward PE Ratio Chart

Sangui Biotech International Annual Data
Trend
Forward PE Ratio

Sangui Biotech International Quarterly Data
Forward PE Ratio

Competitive Comparison of Sangui Biotech International's Forward PE Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Sangui Biotech International's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sangui Biotech International's Forward PE Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Sangui Biotech International's Forward PE Ratio distribution charts can be found below:

* The bar in red indicates where Sangui Biotech International's Forward PE Ratio falls into.



Sangui Biotech International Forward PE Ratio Calculation

It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.


Sangui Biotech International  (OTCPK:SGBI) Forward PE Ratio Explanation

The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.

Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .


Sangui Biotech International Forward PE Ratio Related Terms

Thank you for viewing the detailed overview of Sangui Biotech International's Forward PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Sangui Biotech International (Sangui Biotech International) Business Description

Traded in Other Exchanges
Address
Bleichenbrucke 9, Hamburg, DEU, 20354
Sangui Biotech International Inc develops pharmaceutical, medical and cosmetic products, through its subsidiary. The company develops oxygen carriers for providing oxygen transport in humans due to acute or chronic lack of oxygen and in the case of chronic wounds. It has also developed external applications of oxygen transporters in the form of sprays for healing chronic wounds and gels and emulsions for the regeneration of the skin. The products offered are artificial oxygen carriers; Chitoskin wound pads; and haemoglobin-based wound spray technology sold under the brand name Granulox. It derives revenue from licensing fees on sales of its wound spray product.
Executives
Hubertus Schmelz director NEUER WALL 54, HAMBURG 2M D-20354
Joachim Fleing director ALFRED HERRHAUSENSTR 44, WITTEN 2M 58455
Thomas Striepe director NEUER WALL 54, HAMBURG 2M D-20354
Wolfgang Barnikol director ALFRED HERRHAUSEN STR 44, WITTEN 2M 58455
Lutz Joachim director ALFRED-HERRHAUSEN-ST. 44, WITTEN 2M 58455
Christoph Ludz director SANDERSKOPPEL 17, HAMBURG 2M 22391

Sangui Biotech International (Sangui Biotech International) Headlines

No Headlines